Clevidipine Butyrate (CAS 167221-71-8) Suppliers and Product Information

Clevidipine butyrate is a dihydropyridine calcium channel blocker used as an intravenous agent for the reduction of blood pressure in emergency settings. It is highly selective for vascular smooth muscle and has a rapid onset and offset of action due to its short plasma half-life. The drug is exclusively metabolized in the blood and tissues, avoiding accumulation in the body.

Frequently Asked Questions about Clevidipine Butyrate

Q: What is the primary use of Clevidipine butyrate?

A: Clevidipine butyrate is primarily used as an intravenous treatment for the acute management of hypertension when oral therapy is not feasible or desirable.

Q: How does Clevidipine work?

A: Clevidipine is a blocker of L-type calcium channels, which mediate the influx of calcium during depolarization in arterial smooth muscle. It acts as a potent arterial-specific vasodilator with little to no effect on myocardial contractility and venous capacitance.

Q: What are the advantages of Clevidipine over other intravenous antihypertensive drugs?

A: Clevidipine has a rapid onset and offset of action, and a very short plasma half-life, allowing for precise blood pressure control. Unlike other drugs metabolized in the kidney or liver, Clevidipine is metabolized in the blood and tissues, avoiding accumulation in the body.

Q: Are there any contraindications for Clevidipine use?

A: Clevidipine is contraindicated in patients with severe aortic stenosis, defective lipid metabolism, and allergies to eggs, egg products, soybeans, or soy products.